Hints and tips:
Related Special Reports
...from climate change and medicines to artificial intelligence....
...There will be some things that we just fundamentally don’t feel comfortable taking a human out of the loop for — and maybe that is something like medicine....
...a UK-based short seller that sent its share price plunging by more than 40 per cent and wiped billions off its market value.Gotham City Research released a report on Tuesday accusing the Nasdaq-listed medicine...
...There are a series of big leaps there, but given the state of the world at the moment, it is worth both sides lifting their gaze to the horizon....
...The re-establishment of Horizon relationships offers an opportunity to be more strategic than the “pandemonium” of applications seen pre-Brexit, argued Sir John Bell, regius professor of medicine at Oxford...
About $10bn of loans have been refinanced in public markets as conditions improve due to rate cuts being on the horizon
...Helping researchers identify new medicines for diseases, improving alerts in times of natural disasters, or opening up new opportunities for economic growth are all just as urgent, and will benefit from...
...The FTC argued that Amgen could get buyers such as health insurers to favour Horizon’s drugs by bundling them with its own best selling medicines....
...Medicines price gouger Martin Shkreli was one of a kind. But trustbusters have fresh reasons to feel cross with the pharma industry....
...The FTC had contended that Amgen could get buyers such as health insurers or pharmacy benefit managers to favour Horizon’s drugs by bundling them with its own best-selling medicines....
...The €95.5bn Horizon multilateral research programme is the world’s largest, involving more than 40 countries and covering areas from climate change to new medicines and artificial intelligence....
...White Holes: Inside the Horizon by Carlo Rovelli, translated by Simon Carnell (Riverhead Books/Allen Lane) This slim, speculative volume will enchant the many fans of the stellar cosmologist....
...Not only are the LLM forecasts better when evaluated over the entire period, they are also better for almost all of the individual years in analysis and forecast horizons . . ....
...Sir John Bell Regius Professor of Medicine, University of Oxford; Chairman, Immunocore Dominic Barton Chair, Rio Tinto; Former Global Head, McKinsey & Co Richard Buxton Senior Fund Manager (retired) Sir...
...Many of the foundation’s aims have long time horizons....
...The Medicines and Healthcare products Regulatory Agency, the medicines watchdog, has lost millions of pounds in funding and access to a larger regulatory market....
...Even Griffin, whose last year topped Bridgewater’s Ray Dalio as the most successful hedge fund manager of all time, acknowledged that the end of an era may be on the horizon....
...With more deals on the horizon, DD expects competition between Wall Street’s top investment banks not only to score coveted advisory roles but also to secure the best dealmakers in the energy business....
...Expectations picked up on a three-year horizon, rising to 2.9 per cent from 2.7....
...In Amgen’s case, the FTC argued that the Big Pharma group could get buyers to favour Horizon’s drugs by bundling them with its own best medicines....
...The FTC argued that Amgen could use the rebates it pays on its existing “blockbuster” drugs to press insurance companies and pharmacy benefit managers into paying for two of Horizon’s medicines: Tepezza...
...Atodí’s medicine woman Raimunda de Sousa, a softly spoken lady in simple western dress, led us through the forest to a shack where a group of village women were demonstrating the complex art of processing...
...The FTC argued that Amgen could use the rebates it pays on its “blockbuster” drugs to press insurance companies and pharmacy benefit managers into paying for two of Horizon’s medicines: Tepezza for an autoimmune...
...When announcing the transaction last year, Amgen had said that Horizon’s pipeline of medicines would “strongly complement” its R&D portfolio....
...The talks come during a surge in dealmaking activity in the biopharmaceutical sector as large companies seek to use cash generated during the pandemic to replenish their drug pipelines, as blockbuster medicines...
International Edition